Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 149.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,531 shares of the medical research company's stock after purchasing an additional 2,714 shares during the period. Vontobel Holding Ltd.'s holdings in Charles River Laboratories International were worth $682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Rothschild Investment LLC raised its stake in Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares during the period. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $37,000. GeoWealth Management LLC grew its holdings in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $48,000. Finally, Tortoise Investment Management LLC lifted its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

CRL stock traded up $4.66 during trading on Thursday, reaching $163.63. The company had a trading volume of 825,909 shares, compared to its average volume of 1,029,748. The company has a market cap of $8.04 billion, a price-to-earnings ratio of -251.74, a price-to-earnings-growth ratio of 5.36 and a beta of 1.49. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a 50-day simple moving average of $143.11 and a 200-day simple moving average of $152.16.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $2.27 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRL. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price target for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $174.54.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).